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Objectives. We sought to prospectively identify patients with
stunning and hyperkinesia at hospital discharge on the basis of
mismatches between left ventricular (LV) function and infarct size
as assessed by technetium-99m (Tc-99m) sestamibi perfusion
tomographic imaging.
Background. Mechanical indexes of LV function may not
accurately reflect myocardial damage after acute myocardial
infarction (MI) because of myocardial stunning and compensa-
tory hyperkinesia in noninfarct-related territories. Myocardial
perfusion techniques are unaffected by these variables.
Methods. Eighty-four patients with acute MI underwent hospi-
tal admission and discharge Tc-99m-sestamibi tomographic im-
aging. Global LV ejection fraction (LVEF) was measured at
hospital discharge and 6 weeks later. The perfusion defect size was
quantified and expressed as a percentage of the LV. The discharge
perfusion defect, which is a measure of infarct size, was used to
predict the 6-week LVEF for each patient based on a previously
reported regression equation. Patients were classified into one of
three groups depending on whether their LVEF at hospital
discharge fell within, above or below one standard error (6.8
LVEF points) of the predicted 6-week LVEF.
Results. There were 48 patients classified as having a “match”
between function and infarct size; these patients demonstrated no
significant change in LVEF at 6 weeks. There were 21 patients
(25%) classified as “mismatch stunned” who had discharge
LVEFs lower than those predicted by infarct size. These patients
demonstrated a significant improvement in mean LVEF at 6 weeks
(mean [6SD] discharge LVEF 0.41 6 0.08, 6-week LVEF 0.47 6
0.10; p 5 0.003). Fifteen patients (18%) were classified as
“mismatch-hyperkinetic.” The mean LVEF for these patients
significantly declined at 6 weeks (discharge LVEF 0.64 6 0.06,
6-week LVEF 0.58 6 0.09; p 5 0.002). There was a marked
increase in LVEF within the infarct zone (8 6 15 LVEF points;
p 5 0.03) for patients predicted to have stunning and a marked
decline in LVEF outside the infarct zone (9 6 15 LVEF points; p 5
0.06) in patients predicted to have hyperkinesia. Both discharge
LVEF (p < 0.0001) and group classification (p 5 0.005) were
independent predictors of LVEF 6 weeks later.
Conclusions. Perfusion imaging with Tc-99m-sestamibi can
identify post-MI patients at hospital discharge in whom LV
function is discordant with the measured infarct size. Patients
with stunning have late increases in LVEF; patients with hyperki-
nesia have late decreases. This methodology, performed at dis-
charge, is predictive of late changes in LV function.
(J Am Coll Cardiol 1997;30:1633–40)
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Left ventricular (LV) function is an important predictor of
patients’ prognosis after myocardial infarction (MI) (1,2) and
is linearly related to infarct size (3). It is now well established
that impaired LV function, especially in the immediate post-
reperfusion setting, may not represent an irreversible state (4).
Multiple reports have described a delayed improvement in left
ventricular ejection fraction (LVEF) and regional wall motion
in some patients who received acute reperfusion therapy
during MI, presumably secondary to recovery of stunned
myocardium (5–9). Consequently, early indices of mechanical
function may be inaccurate in up to one-third of post-MI
patients who receive early reperfusion therapy (6).
Technetium-99m (Tc-99m) sestamibi uptake and retention
are generally not affected by myocardial stunning (10). Owing
to favorable imaging qualities, infarct size with Tc-99m sesta-
mibi can be accurately quantified (11–14). A previous study
demonstrated that infarct size measured by Tc-99m sestamibi
was linearly related to LV function 6 weeks after the index
event in patients receiving early reperfusion therapy. It was
evident that these measures could potentially be used to
prospectively identify patients with myocardial stunning (6).
The purpose of this study was to prospectively identify patients
with stunning and hyperkinesia at hospital discharge on the
basis of identifying mismatches between LV function and
infarct size measured by Tc-99m sestamibi tomographic imag-
ing in a separate patient cohort.
Methods
Study group. The study group consisted of a consecutive
series of patients enrolled in a prospective trial (15) of Tc-99m
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sestamibi between 1988 and 1992 who met the following
inclusion criteria: 1) chest pain $30 min in duration; 2)
electrocardiographic (ECG) ST segment elevation at least 0.1
mV in two or more leads in the same vascular territory; 3)
significant elevation in creatine kinase, MB isoenzyme within
24 h of chest pain; and 4) rest equilibrium gated radionuclide
ventriculography performed at hospital discharge and at 6
weeks after the infarction. Exclusion criteria included 1)
recurrent acute MI (n 5 1) or a coronary revascularization
procedure between hospital discharge and 6 weeks (n 5 5); 2)
left bundle branch block, ventricularly paced rhythm or ven-
tricular pre-excitation syndrome; 3) atrial fibrillation during
radionuclide ventriculography; and 4) inclusion in a previous
study on myocardial stunning (6). Eighty-four patients met
these criteria and formed the study group.
Radionuclide studies. Technetium-99m sestamibi tomo-
graphic acquisitions were performed on hospital admission and
at discharge 1 to 6 h after injection of 20 to 30 mCi of
Tc-99m-sestamibi using a previously described technique (14–
16). For acute imaging, Tc-99m-sestamibi was injected before
any reperfusion therapy, and acquisition was delayed until
completion of the therapy (16–19). Quantification of the
extent of LV severe hypoperfusion was performed from five
short-axis slices using a 60% of maximum counts threshold
method, which has been previously described (14–16). The
extent of the acute and discharge defects is a measure of
myocardium at risk and infarct size, respectively, with the
difference (acute-discharge defect extent) reflecting myocar-
dial salvage (10,17). Measures of myocardium at risk by
Tc-99m-sestamibi in animal models of permanent coronary
occlusion as well as after reperfusion have been validated
(12,18). Quantified infarct size with Tc-99m sestamibi has been
extensively studied. This measure has been carefully validated
in animal models of coronary occlusion and reperfusion
(11,18). It has correlated closely with other clinical markers of
infarct size, including cardiac enzyme release (20), global and
regional systolic function (6,13,21), thallium defect size (22)
and human pathology (23).
Gated equilibrium radionuclide ventriculography with Tc-
99m labeled red blood cells was performed at hospital dis-
charge (1 day after Tc-99m-sestamibi imaging) and at 6 weeks
using the modified in vivo method of Callahan et al. (24).
Gated images were acquired and processed using previously
described techniques (25). Global LVEF was calculated from
the background-corrected LV counts versus the time curve by
use of a commercially available operator-interactive program
(25). The standard deviation (SD) of the difference between
repeat measurements obtained by this technique is 0.04 (26).
The 95% confidence limit for a definite change in LV ejection
fraction (LVEF) was therefore considered to be $0.08 and a
probable improvement (67% confidence limits) was a change
of .0.04.
Regional LVEF was obtained by dividing the LV region
into four quadrants in the 45° left anterior oblique view from a
fixed center derived from the end-diastolic images (27). These
quadrants defined the anterior, septal, inferior and lateral
territories. Regional changes in LVEF were classified as within
the infarct zone and outside the infarct zone. The anterior
quadrant was excluded, as it represents primarily valve plane
motion. For patients with an anterior infarction, the infarct
zone consisted of the septal quadrant. For patients with an
inferior or lateral infarction, the corresponding quadrant was
defined as the infarct zone. The two quadrants not in the
infarct zone were averaged to obtain representative values
outside the infarct zone. The SD of reproducibility of this
methodology is 3.5 LVEF points for intraobserver measure-
ments and 4.2 LVEF points for interobserver measurements
(27). Six patients did not have regional LVEF values
calculated because their data could not be retrieved from
the archive.
Predicted global late LVEF. A predicted global LVEF was
calculated for each patient based on the previously reported
relation between infarct size by Tc-99m sestamibi and LVEF 6
weeks later in a separate patient cohort (6). The equation of
this regression line was:
Predicted LVEF 5 ~ 2 0.47! ~Infarct size @%LV#! 1 58
The correlation (r) and standard error of the estimate
(SEE) were 20.81 and 0.067, respectively (Fig. 1).
By design, none of the patients used to derive this regres-
sion equation of predicted LVEF are included in this report.
For the present study, those patients whose discharge LVEF
fell within 1 standard error (SE) of their predicted LVEF 6
weeks later were assigned to the “matched” group; no signif-
icant change in 6-week LVEF was predicted for this group
(Fig. 1). Patients whose discharge LVEF was .1 SE above the
predicted late LVEF were classified as “mismatched-
hyperkinetic.” These patients were expected to have a decrease
in their global LVEF between hospital discharge and 6 weeks.
Patients whose global LVEF at discharge was .1 SD below the
predicted LVEF were classified as “mismatched-stunned.”
These patients were expected to have a significant increase in
their global LVEF between discharge and 6 weeks.
Statistical analysis. Data are presented as mean values 6
SD. Simple linear regression analysis was used to compare
Tc-99m sestamibi defect size with LVEF at hospital discharge.
Repeated measures analysis of variance (ANOVA) was used
to compare LVEF at discharge and 6 weeks later. One-factor
ANOVA was used to compare changes in global and regional
LVEF by group classification. Analysis of covariance
(ANCOVA) was performed to make certain that changes in
Abbreviations and Acronyms
ANCOVA 5 analysis of covariance
ANOVA 5 analysis of variance
ECG 5 electrocardiogram, electrocardiographic
LV 5 left ventricle, left ventricular
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
Tc-99m 5 technetium-99m
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LVEF between hospital discharge and 6 weeks were not solely
a function of the discharge LVEF (regression to mean). In this
analysis the dependent variable was 6-week LVEF and the
independent variables were discharge LVEF and group assign-
ment. A value ,0.05 was considered significant. All analyses
were done using commercially available statistical software
(Statview 4.1 and Superanova 1.0, Abacus concepts).
Results
The clinical characteristics of the study group are detailed
in Table 1. The relation between global LVEF and predicted
LVEF, based on the perfusion defect size for each patient,
is shown in Figure 1. Patients were classified on the basis of
this relation into three groups. There were 48 patients
(57%) whose discharge LVEF was within 1 SE of the
previously reported regression line relating discharge infarct
size by Tc-99m sestamibi with 6-week LVEF. Twenty-one
patients (25%) had a LVEF .1 SE below the regression line
(mismatch-stunned). Clinical characteristics were similar by
group classification, with the exception of infarct location.
There was a greater percentage of patients with an anterior
infarction in the mismatch-stunned group (67%) and a
lower percentage of patients with an anterior infarction in
the other two groups. Acute reperfusion therapy was given
to 79 of 84 patients; 38 underwent direct percutaneous
transluminal coronary angioplasty and 41 received intrave-
nous thrombolytic therapy. There were no differences in
reperfusion modality or time to reperfusion therapy be-
tween the groups.
Perfusion imaging variables (Table 2). There was a trend
(p 5 0.08) toward a difference in myocardium at risk between
the groups. Myocardium at risk tended to be greater for
patients classified as “mismatch-stunned” (39 6 21% of the
LV) compared with those classified as matched (30 6 19% of
the LV) or mismatched-hyperkinetic (25 6 20% of the LV).
There was no difference in infarct size between the groups,
however. Consequently, the mean predicted global LVEF for
all three groups was similar. Myocardial salvage was greatest
for patients classified as “mismatch-stunned”, and there was a
significant (p 5 0.03) difference in myocardial salvage between
the three groups.
Global LV function (Fig. 1 to 3, Table 2). LVEF at hospital
discharge was well preserved for the study group (0.51 6 0.11),
and there was no significant overall change at 6 weeks (0.52 6
0.10). The mean predicted LVEF for the study group was not
significantly different from either of the actual acquisitions
(0.52 6 0.07).
However, there were significant differences in LVEF be-
tween the groups. The mismatch-stunned group had an initially
low mean LVEF of 0.41 6 0.08, which improved significantly
by 6 weeks (6-week LVEF 0.47 6 0.10, p 5 0.003 vs. discharge
LVEF). However, these values were still significantly lower
than predicted (0.52 6 0.07, p 5 0.004 vs. 6-week LVEF). On
an individual basis, 13 (62%) of 21 patients in the mismatch-
stunned group had a probable improvement in LVEF (.0.04)
and 7 (33%) of 21 had a definite improvement (.0.08).
The mismatch-hyperkinetic group had a high LVEF of
0.64 6 0.06. At 6 weeks these values had declined to 0.58 6
0.09 (p 5 0.002 vs. discharge LVEF), but were still significantly
Table 1. Clinical Characteristics by Classification
Overall
(n 5 84)
Match
(n 5 48)
Mismatch-
Stunned
(n 5 21)
Mismatch-
Hyperkinetic
(n 5 15) p Value*
Age (yr) 60 6 11 59 6 12 60 6 12 66 6 10 0.13
Male 74% 79% 62% 73% NS
Anterior location 37% 29% 67% 20% 0.01
Acute reperfusion therapy
(PTCA/thrombolysis)
45%/49% 46%/50% 48%/48% 40%/47% NS
Time to reperfusion therapy (h) 4.5 6 3.6 4.5 6 3.3 4.5 6 3.9 4.5 6 4.2 NS
*Analysis of variance between the three group classifications. Data are presented as mean values 6 SD or
percentages. PTCA 5 percutaneous transluminal coronary angioplasty.
Figure 1. Previously derived relation between infarct size by Tc-99m
sestamibi and LVEF 6 weeks later in a separate group of 32 patients
undergoing successful reperfusion therapy. Central line 5 line of
regression, upper and lower lines 5 boundaries of 1 SEE from the
regression line. The three classification groups are represented by the
differently shaded regions. Data points from the 84 patients in the
present study are superimposed over the previously defined relation
between discharge infarct size and 6-week LVEF. These values reflect
discharge LVEF. Most patients fell within the previously derived
range, but there were outliers in both directions. These patients were
predicted to move into the predicted range (matched zone) 6 weeks
later.
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higher than predicted (0.52 6 0.06, p 5 0.008 vs. 6-week
LVEF). Nine (60%) of 15 patients had a probable decline in
LVEF ($0.04) and 7 (47%) of 15 had a definite decline
($0.08). The matched group showed no significant group
change in LVEF (0.52 6 0.08 at discharge vs. 0.52 6 0.10 at 6
weeks, p 5 NS), and neither value was different from the
predicted LVEF based on perfusion defect size at discharge
(0.52 6 0.07). There were fairly equal percentages of patients
demonstrating a probable increase (25%) as well as a probable
decrease (29%) in LVEF and for those demonstrating a
definite increase (12%) and decrease (10%).
Regional changes in LV function (Fig. 4, Table 3). Within
the infarct zone. There was a significant difference (p 5 0.002)
in regional LVEF within the infarct zone between the three
groups (Table 3), with the mismatch-stunned group showing
the lowest and the mismatch-hyperkinetic group showing the
highest values. This difference resolved at 6 weeks. An overall
significant improvement in regional LVEF from hospital dis-
charge to 6 weeks occurred within the infarct zone (0.52 6 0.17
at discharge to 0.55 6 0.16 at 6 weeks, p 5 0.05). This change
was primarily due to an improvement in the regional LVEF
within the infarct zone for patients classified as mismatch-
stunned (0.42 6 0.17 to 0.50 6 0.15, p 5 0.03). The change in
regional LVEF within the infarct zone (6 week–discharge) is
shown in Figure 4A. There was a strong trend toward a
difference in the change in LVEF within the infarct zone by
group classification.
Outside the infarct zone. There was no overall change in
LVEF outside the infarct zone for the study group as a whole
(Table 3). There were significant differences in regional LVEF
values at hospital discharge by group classification, with the
mismatch-hyperkinetic group having the highest and the
mismatch-stunned group having the lowest values (p ,
0.0001). Consistent with the analysis within the infarct zone,
this difference was no longer significant at 6 weeks. The largest
magnitude of change (a decrease in LVEF) was found in the
mismatch-hyperkinetic group (p 5 0.06, Table 3). The overall
differences in the change in regional LVEF outside the infarct
zone was significant by classification group (Fig. 4B).
Multivariate analysis. Because of the differences in dis-
charge global LVEF between the groups, it is conceivable that
the differences in the change in LVEF from discharge to 6
weeks between the groups might merely represent regression
to the mean. However, by ANCOVA, both discharge EF (p ,
Table 2. Radionuclide Variables by Classification (expressed as percent of left ventricle)
Overall
(n 5 84)
Match
(n 5 48)
Mismatch-
Stunned
(n 5 21)
Mismatch-
Hyperkinetic
(n 5 15) p Value*
Perfusion
Myocardium at risk 31 6 20 30 6 19 39 6 21 25 6 20 0.08
Infarct size 13 6 15 13 6 15 13 6 16 14 6 14 NS
Salvage 18 6 17 17 6 16 26 6 18 12 6 16 0.03
Left Ventricular Function
Predicted LVEF 0.52 6 0.07 0.52 6 0.07 0.52 6 0.07 0.52 6 0.06 NS
Discharge LVEF 0.52 6 0.11 0.52 6 0.08 0.41 6 0.08 0.64 6 0.06 , 0.0001
6-week LVEF 0.52 6 0.10 0.52 6 0.10 0.47 6 0.10 0.58 6 0.09 0.007
6 week vs. discharge
LVEF
0 6 0.08 0 6 0.06 0.06 6 0.08 20.06 6 0.06 , 0.0001
*Between-group analysis of variance. Data are presented as mean values 6 SD. LVEF 5 left ventricular ejection
fraction.
Figure 2. Discharge and 6-week LVEF values for
each patient according to the three prospective
classifications. There was a significant increase in
LVEF in the “mismatch-stunned” group and a
significant decrease in LVEF in the “mismatch-
hyperkinetic” group. Mean values are shown by
solid lines with open circles. EF 5 ejection
fraction.
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0.0001) and group classification (p 5 0.005) were independent
determinants of 6-week LVEF.
Discussion
Myocardial stunning is characterized by a mismatch of
myocardial perfusion (normal) and function (depressed)
within viable myocardium, which improves spontaneously over
time. There are relatively few clinical studies that directly
examine both perfusion and function to identify myocardial
stunning. Most studies have deduced the presence of myocar-
dial stunning by a temporal resolution in myocardial dysfunc-
tion (5,7–9). However, to accurately diagnose the presence of
Figure 3. Scatterplots by prospective classification group by initial and
late LVEF. A, Match group; B (stunning) and C (hyperkinetic),
mismatch groups. Dashed line 5 line of identity. The majority of
patients in the two mismatch groups (B and C) are on one side of the
line of identity. The distribution is more equal in the match group (A).
The relation between initial and late LVEF was significantly different
(p 5 0.005) between the three groups.
Figure 4. Change in regional LVEF values (6 weeks vs. discharge) by
group classification. A, Within the infarct zone. B, Outside the infarct
zone. Data are presented as mean values 6 SD.
Table 3. Regional Left Ventricular Ejection Fraction Values
No. of
Pts Discharge 6 Weeks
p Value
(discharge
vs. 6 weeks)
Within infarct zone
Overall 78 0.52 6 0.17 0.55 6 0.16 0.05
Match 46 0.53 6 0.14 0.55 6 0.15 .0.20
Mismatch-stunned 20 0.42 6 0.17 0.50 6 0.15 0.03
Mismatch-hyperkinesia 12 0.63 6 0.19 0.60 6 0.20 .0.20
p 5 0.002* p . 0.20†
Outside infarct zone
Overall 78 0.51 6 0.13 0.52 6 0.13 .0.20
Match 46 0.50 6 0.11 0.52 6 0.11 .0.20
Mismatch-stunned 20 0.44 6 0.14 0.49 6 0.14 0.12
Mismatch-hyperkinesia 12 0.65 6 0.10 0.56 6 0.15 0.06
p , 0.0001* p . 0.20†
*Analysis of variance between-group classification for regional left ventric-
ular ejection fraction at discharge. †Analysis of variance between-group classi-
fication for regional left ventricular ejection fraction at 6 weeks. Pts 5 patients.
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uncoupling of flow and contractility, both flow and function
must be simultaneously evaluated.
The present study was designed to simultaneously measure
indices of perfusion and LV systolic performance at the time of
discharge in postinfarction patients to identify discordance
between these two variables. Technetium-99m sestamibi is
uniquely suited to assess perfusion and infarct size because of
its linear uptake with myocardial blood flow (28) and the
optimal physical characteristics that allow for accurate quan-
tification of infarct size (14). Uptake and retention of Tc-99m-
sestamibi is dependent on cellular viability (10,29). Conse-
quently, myocardial perfusion can be assessed within the LV
and the extent of infarction can be defined. The uptake and
retention of the tracer to assess perfusion do not appear to be
affected by myocardial stunning (6,10).
The mechanisms that produce stunning have not been
unequivocally defined; actually, a combination of factors may
be involved (30). Oxygen free radicals indiscriminately disrupt
metabolic pathways. It has been postulated that the generation
of oxygen free radicals from reperfusion flow may interfere
with the function of sarcoplasmic reticulum, producing calcium
overload in the cytosol (31). Technetium-99m sestamibi is
largely sequestered within mitochondria owing to its large
cationic charge (32). Consequently, there is no physiologic
reason to suspect its uptake and retention are affected by the
presence of stunning so long as blood flow is restored. Sinusas
et al. (10), in a carefully designed series of experiments, have
demonstrated that sestamibi kinetics within myocytes are
unaffected by the presence of stunning produced in an animal
model. Based on these observations and other published data
demonstrating the lack of uptake in regions of infarcted
myocardium despite reperfusion flow (12,18), Tc-99m-
sestamibi is an attractive agent used to help study myocardial
stunning.
A previously derived relation between infarct size with
Tc-99m sestamibi and LVEF 6 weeks later (when stunning is
likely to have resolved) was used to generate a predicted late
LVEF in a separate patient group. Discordance between the
actual LVEF at discharge and the predicted late LVEF was
used to identify patients likely to demonstrate significant
changes in global LV function (6). These classifications were
reasonably accurate. For patients classified as having myocar-
dial stunning, there was a significant increase in mean global
LVEF over time, and 60% of patients had an improvement in
LVEF. Mean regional LVEF values showed a significant
improvement in contractility within the infarct zone in these
prospectively classified patients. It is of interest that patients in
this group predominantly had an anterior infarction and,
consequently, a greater amount of myocardium at risk and
subsequent myocardial salvage (17). The larger territory ex-
posed to reperfusion flow may have predisposed these patients
to more clinically significant depression in LV function. For
patients whose LVEF was inappropriately high for the extent
of infarction, there was a significant decline for the group as a
whole, and the majority of patients (60%) showed a probable
decline in LVEF. Regional LVEF values showed a marked
decline outside the zone of infarction for this subgroup of
patients, which was not apparent in the other two subgroups.
This phenomenon in post-MI patients has been previously
described and may be related to fluctuations in catecholamine
release (33).
The temporal changes in LV function found in this study
are in agreement with several previous reports that suggest
that stunning at the time of hospital dismissal is present in only
a portion of patients receiving reperfusion therapy (6,34).
Overestimation of LV function from compensatory hyperkine-
sia is as likely to be present as stunning after reperfusion
therapy. Bestetti et al. (34) found that 30% of patients treated
with thrombolysis had a significant improvement in LV func-
tion from 3 weeks to 6 months after the index infarction (34).
The percentage of patients showing late improvement in
LVEF in this study (25%) is similar to that in the pilot data (6)
on which this study was based (15%). The percentage of
patients showing a late decline in LVEF was identical in this
study and the pilot study (18% for both) (6). As in the pilot
study (6) and other reports (35), those patients showing
improvement had a lower LVEF initially; those showing a
decline had higher LVEF values initially. To our knowledge,
this is one of the first studies to propose a methodology to
predict future changes in LV function at a time point where
clinical decisions regarding therapy are often required.
Study limitations. Follow-up imaging of the study group
only extended to 6 weeks after the index infarction and no
later. This prevents any exploration of the more prolonged
condition of myocardial hibernation, which has been reported
by others using Tc-99m sestamibi imaging after infarction
(36,37).
It is conceivable that all the directional changes in LVEF
are merely due to regression to the mean; patients with a “low”
LVEF at hospital discharge will tend to increase on retesting.
To adjust for this effect, we used a multivariate analysis with
group classification and discharge LVEF as factors in deter-
mining the association with 6-week LVEF. If all the results
could be explained by this phenomenon, then the factor of
group classification should not be an independent predictor of
6-week LVEF once the discharge LVEF was known. Because
group classification was significant and independent of the
discharge LVEF, the results cannot be solely attributed to
regression to the mean, but this phenomenon could still be
partially responsible for the directional changes seen within the
groups.
The directional changes seen on the regional LVEF analysis
were similar both inside and outside the infarct zone. Although
the LVEF in the stunned group improved significantly within
the infarct zone, it also tended to improve outside the zone. A
similar pattern of declining LVEF was seen in the hyperkinetic
group. This may reflect extensions of these physiologic effects
beyond the boundaries defined by the segments on the radio-
nuclide angiogram, which are only approximations of the
expected extent of an infarct by location. It should be noted
that the reproducibility of regional LVEF values may not be as
precise compared with the global determination of LVEF.
Consequently, the regional findings should be interpreted with
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more caution. The measurement of LVEF may be less accu-
rate in the presence of mitral regurgitation and apical aneu-
rysms.
Conclusions. This study provides a unique method to
prospectively identify patients with stunning or hyperkinesia
fairly early (;1 week) after the index infarction, using rest
tomographic imaging with Tc-99m sestamibi. The simulta-
neous assessment of global LV function from first-pass Tc-99m
sestamibi acquisitions (38) and gating of the perfusion images
(39) are an attractive method to assess both perfusion and
function in a single study. Other techniques may hold promise
in this regard (40,41). The goal should be to assess both
perfusion and function early to identify patients likely to
demonstrate late changes in systolic performance. Mismatches
between function and perfusion at ;1 week after reperfusion
therapy for acute MI are present in a little over one-third of
patients.
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